Reported Earlier, 180 Life Sciences Regains Full Compliance With Nasdaq Listing Standards
Reported Earlier, 180 Life Sciences Regains Full Compliance With Nasdaq Listing Standards
早前报道，180 Life Sciences 完全符合纳斯达克上市标准
180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.
180生命科学公司（"180"或"公司"）高兴地宣布，已经重新符合纳斯达克上市规则5605(c)(2)，该规则要求纳斯达克上市公司维持由三名独立董事组成的审计委员会。此次进展是继史蒂芬·舒梅克先生被任命为公司独立董事及审计委员会成员后。随着这项任命，180现在完全符合所有纳斯达克的持续上市要求，并已纠正所有之前公告的缺陷。